THCJD
THCJD at a glance
Naturally occurring
Psychoactive
Cannabinoid type
Discovery year
Also known as
Molecular formula
C24H36O2
CB1 receptor interaction
CB2 receptor interaction
What is THCJD?
THCJD is a rare intoxicating phytocannabinoid and the eight-carbon homologue of Delta-9-THC. It has been reported naturally in hemp in trace amounts, while commercial THCJD is produced synthetically because natural concentrations are extremely low. THCJD is commonly considered around 10× as psychoactively potent as Delta-9-THC, although its actual human potency has not been established in controlled studies.
THCJD has the same basic THC structure as Delta-9-THC but contains an eight-carbon (octyl) side chain instead of the five-carbon (pentyl) side chain of Delta-9-THC. This unusually long side chain is expected to substantially increase cannabinoid activity. Delta-8-THCJD is a separate positional isomer that also exists and has been studied.
Commercial THCJD is produced synthetically and generally supplied as a high-purity distillate. Its appearance is typically vicious and amber-coloured. Compound-specific information about its long-term stability and degradation remains extremely limited.
THC analogues with an eight-carbon (octyl) side chain were first explored during early cannabinoid research in the 1940s, but THCJD received very little attention for decades. Interest increased substantially with the emergence of long-chain cannabinoids such as THCP and the modern commercial cannabinoid market. Scientific research on THCJD remains extremely limited, particularly regarding human potency, safety and pharmacokinetics.
How THCJD works in the human body
THCJD activates CB1 as agonist and is involved in intoxication and neurological effects. It’s theoretically estimated at around 3x the psychoactive potency of Delta-9-THC. Research suggests unusually high CB1 efficacy, but different experimental measures do not consistently show the same unusually high potency. Its metabolism and active metabolites have not yet been established.
CB1 receptor
The main cannabinoid receptor in the brain, responsible for THC’s intoxicating effects. THCJD acts as a CB1 agonist. Direct binding research found that Delta-8-THCJD has approximately 4.8x stronger CB1 binding affinity than Delta-8-THC under the same experimental conditions. Animal research also found strong cannabinoid activity for Delta-8-THCJD, with substantially lower doses required to produce effects in pain-response, movement and hypothermia tests.
More recent research directly tested THCJD at the human CB1 receptor. Compared with Delta-9-THC, THCJD showed approximately 0.44x the functional potency, meaning a higher concentration was required to activate the receptor. However, it reached approximately 1.56x the maximum response of Delta-9-THC, indicating greater efficacy once sufficient receptor activation occurred.
A longer alkyl side chain in THC homologues is associated with stronger CB1 binding, but this relationship appears to have an upper limit. The exact optimal side-chain length has not been confirmed, but research suggests that extending the chain beyond seven carbons (THCP) does not further improve CB1 binding much. It’s likely that THCP and THCJD are the optimal length for CB1 activation, and any longer side chain could reduce psychoactive effects.
Taken together, the approximately 4.8x stronger binding of Delta-8-THCJD, 2.8 to 4.2x greater potency in mouse behavioural tests, and higher maximum CB1 response but lower functional potency of Delta-9-THCJD suggest that the receptor evidence does not support a simple potency conversion. Combining these findings, THCJD is theoretically estimated at around 3x the psychoactive potency of Delta-9-THC.
CB2 receptor
The main cannabinoid receptor in the immune system, involved in regulating immune cell activity and inflammatory responses. No CB2 binding data have been published for either the delta-8 or delta-9 form of THCJD. Because a longer side-chain has been shown in other THC homologues, to increase CB2 binding and activation, a similar pattern is plausible for THCJD, but this is a logical assumption rather than a direct measurement, so it carries more uncertainty than the CB1 estimate above.
Metabolism
THCJD metabolism has not been researched in humans. Based on Delta-9-THC and other longer-chain THC homologues, hydroxylation followed by further oxidation is plausible. A THCJD metabolite like 11-OH-THCJD could theoretically be very active, similar to 11-OH-THC, but neither its formation nor psychoactivity has been confirmed.
Human safety status
No controlled human safety or systematic toxicology studies have established the safety profile of THCJD. Acute intoxications involving products containing both Delta-8- and Delta-9-THC-C8 have been reported, but these mixed exposures cannot establish the effects of THCJD alone. Direct organ toxicity or chronic toxicological damage specific to THCJD has not been demonstrated, while repeated and long-term exposure remain unstudied.
THCJD interactions with other compounds
Important disclaimer
This information is provided for educational and technical reference only. Interaction data can change as new research becomes available and may be incomplete or outdated. The real relevance of any interaction depends strongly on dose, route of administration, timing, formulation and individual metabolism. Readers should do their own research and consult a qualified healthcare professional before making decisions involving medicines, alcohol, nicotine, cannabinoids or other compounds. Elementra's products and information are intended for research, production and technical use only and are not intended for human consumption.
No Known Interactions Identified
Current Evidence
Limited Data
No sufficiently supported specific interactions between THCJD and other cannabinoids, common substances or medicines have currently been identified. THCJD has been directly studied for cannabinoid receptor activity, but research has not yet shown that another compound meaningfully changes its exposure or effects, or that THCJD meaningfully changes the exposure or effects of another compound. This should not be interpreted as THCJD having no interactions. Interactions may exist, but they have not yet been identified or characterized by research.
This content does not constitute advice
All information in the Cannabinoid Knowledge Hub is provided solely for educational and scientific purposes. It does not constitute medical advice, usage advice, dosage guidance or instructions for mixing, combining or consuming substances.
Discussions of effects, interactions and risks are descriptive only and should not be interpreted as a recommendation or encouragement to use or combine any substance. Visitors are responsible for complying with all applicable laws and regulations in their country or jurisdiction. Nothing in the Knowledge Hub may be used to support illegal activity.
Read the full disclaimer